Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Late April and early May are the most flourish times in Denmark. The leaves are sprouting on the trees, the grass is growing quickly, weeds are coming to life and in many places in Denmark the yellow ...

Copenhagen Municipality has completed its first comprehensive mapping of biodiversity across the city. The new report outlines areas where there is potential to preserve, improve, or expand ...

Trump's mercantilist approach to foreign policy has caused transatlantic tensions. European allies are considering how to ...

Hours before Trump announced he was pausing all tariffs except those on China, the EU voted to hit back with counter-tariffs ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...

MONDAY, April 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic ...